scispace - formally typeset
Search or ask a question

Showing papers by "Jacques Buvat published in 2016"


Journal ArticleDOI
TL;DR: PDE5 inhibitors remain a first-line treatment option because of their excellent efficacy and safety profile and intraurethral and topical alprostadil provide an alternative, less invasive treatment option.

147 citations